An observational study in Diabetic Retinopathy, sponsored by Association for Innovation and Biomedical Research on Light and Image. Recruiting at 1 site in Portugal. Open to participants aged 35 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Association for Innovation and Biomedical Research on Light and Image · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image — 2 open to participants now, 3 under way, none of them phase 3. Diabetic Retinopathy · Association for Innovation and Biomedical Research on Light and Image.
Among the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, this one is the 2nd largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2025, is one of 16 observational ones, and was the 17th registered.
783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.
Browse Diabetic Retinopathy studies →2 of the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image are open now, in 1 country. Recruiting first, the newest first:
Association for Innovation and Biomedical Research on Light and Image · Sites in Portugal
Ages 35–80
By country, each count listing its studies:
Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.
This study: 35 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 1,000 is above the median of 173 across 265 observational studies indexed under Diabetic Retinopathy.
Median enrollment 84 across the 2 interventional studies, 81 across the 16 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Association for Innovation and Biomedical Research on Light and Image is the lead sponsor of 38 studies on the registry; 5 are open to participants now.
2 of the studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07417410Association for Innovation and Biomedical Research on Light and ImageAnalysis of DR Progression to Identify Risks and Need for Treatment | 2026-11 |
| NCT07458516Association for Innovation and Biomedical Research on Light and ImageLongitudinal Observational Study of Diabetic Retinopathy Progression in Type 2 Diabetes Patients | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Diabetic Retinopathy by Association for Innovation and Biomedical Research on Light and Image, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to understand whether vascular and structural changes in the eyes caused by diabetes can help predict which people are more likely to experience worsening diabetic retinopathy (a diabetes-related eye disease) and how these eye changes are related to cardiovascular complications.
The study will include about 1,000 people with type 2 diabetes, aged 35 to 90 years, and will take place over twelve months. It may also include a retrospective component, where existing medical and imaging data collected from previous visits (within the last 1 to 5 years) will be analyzed.
The main questions it aims to answer are:
Diabetic Retinopathy (DR) is a leading cause of vision loss in adults with type 2 diabetes (T2D) and is associated with systemic complications, including cardiovascular disease. Early identification of patients at high risk of DR progression and cardiovascular events is critical to optimizing clinical management. Retinal imaging biomarkers, combined with clinical and demographic data, provide an opportunity to better understand disease mechanisms, predict progression of DR and associated cardiovascular complications, and guide personalized interventions.
The aim of this study is to investigate the influence of central versus peripheral retinal lesions on DR progression and staging, characterize associations between retinal biomarkers and cardiovascular risk factors and major adverse cardiovascular events (MACE), and contribute to the understanding of pathophysiological mechanisms underlying DR in T2D patients. The study will also generate a high-quality, harmonized database to support the development of artificial intelligence (AI) models.
This study aims to determine the extent to which central and peripheral retinal lesions, together with quantitative imaging biomarkers, contribute to the progression and staging of DR and the occurrence of cardiovascular complications in patients with T2D. Additionally, in the scope of the ALERT project (supported by Fundação para Ciência e Tecnologia (FCT); COMPETE2030-FEDER-00921900), the data of this clinical study will be used to create a harmonized, high-quality database for the development of exploratory interpretable artificial intelligence models for predicting DR progression and stage as well as predict the values of cardiovascular risk factors, and the risk of developing cardiovascular complications.
1.000 participants with T2D will be included in this study, in a recruitment period of 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change in Diabetic Retinopathy Staging
Change in score on the Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale (ETDRS DRSS; range 10-85; higher scores indicate worse severity), measured on Optos Ultra-Widefield Fundus Photography.
Time frame: Baseline to 12 months
Diabetic Retinopathy (DR) Progression, measured on the OPTOS Ultra-widefield Fundus Photography (UWF-FP)
Defined as a ≥2-step worsening on the Early Treatment Diabetic Retinopathy Study Diabetic Retinopathy Severity Scale (ETDRS DRSS)
Time frame: Baseline to 12 months
Proportion of participants with ≥15-letter loss in ETDRS Best-Corrected Visual Acuity (BCVA)
≥15-letter loss on the ETDRS BCVA chart (measured with Snellen or LogMAR charts converted to the ETDRS scale).
Time frame: Baseline to 12 months
Incidence of Major Adverse Cardiovascular Events (MACE)
Incidence of myocardial infarction, ischemic stroke, or hospitalization for heart failure, extracted from medical history and confirmed by investigator.
Time frame: Baseline to 12 months
Number of microaneurysms in the central ETDRS area (90°)
Count of microaneurysms within the central ETDRS grading area (90 degrees), assessed by human graders on Optos Ultra-Widefield Fundus Photography images.
Time frame: Baseline to 12 months
Number of microaneurysms in the peripheral retina (90-200°)
Count of microaneurysms in the peripheral retinal area (between 90 and 200 degrees), assessed by human graders on Optos Ultra-Widefield Fundus Photography images.
Time frame: Baseline to 12 months
Presence of hemorrhages in the central ETDRS area
Presence of retinal hemorrhages within the central ETDRS grading area (90 degrees), identified by human graders on Optos Ultra-Widefield Fundus Photography. Reported as the percentage of affected eyes.
Time frame: Baseline to 12 months
Presence of peripheral retinal hemorrhages (90-200°)
Presence of retinal hemorrhages in the peripheral retina (90-200 degrees), assessed through human grading of Optos Ultra-Widefield Fundus Photography images. Reported as the percentage of affected eyes.
Time frame: Baseline to 12 months
Presence of exudates in the retina
Presence of hard exudates identified by human graders on Optos Ultra-Widefield Fundus Photography. Reported as the percentage of eyes displaying ≥1 exudate.
Time frame: Baseline to 12 months
Presence of cotton wool spots in the retina
Presence of cotton wool spots identified by human graders on Optos Ultra-Widefield Fundus Photography. Reported as the percentage of affected eyes.
Time frame: Baseline to 12 months
Correlation between retinal microaneurysm count and glycated hemoglobin (HbA1c)
Correlation between the number of microaneurysms identified on Optos Ultra-Widefield Fundus Photography and (HbA1c) levels obtained through clinical laboratory testing. Reported as a correlation coefficient (r).
Time frame: Baseline to 12 months
Retinal vessel density
Quantitative vessel density measured using Optical Coherence Tomography Angiography. Expressed in inverse millimeters (mm-1)
Time frame: Baseline to 12 months
Correlation between retinal vessel density and systolic blood pressure
Correlation between vessel density quantified using Optical Coherence Tomography Angiography and systolic blood pressure collected during clinical evaluation. Reported as a correlation coefficient (r).
Time frame: Baseline to 12 months
Abnormal intercapillary spaces (AIS) in the retina
Count of abnormal intercapillary spaces assessed using Optical Coherence Tomography Angiography automated analysis tools. Expressed as the percentage of pixels associated with the presence of abnormal intercapillary spaces relative to the total number of pixels in the slab.
Time frame: Baseline to 12 months
Correlation between abnormal intercapillary spaces (AIS) and major adverse cardiovascular events (MACE)
Correlation between the number of abnormal intercapillary spaces measured on Optical Coherence Tomography Angiography and the occurrence of (MACE). Reported as a correlation coefficient (r).
Time frame: Baseline to 12 months
Retinal venous calibre
Mean venous calibre measured in micrometers (μm) through automated analysis of Color Fundus Photography images.
Time frame: Baseline to 12 months
Retinal vascular tortuosity
Vascular tortuosity calculated from Color Fundus Photography images using validated image analysis algorithms.
Time frame: Baseline to 12 months
Microaneurysm turnover (MAT) over one year
Number of microaneurysms appearing and disappearing over a one-year period, quantified through automated analysis of sequential Color Fundus Photography images.
Time frame: Baseline to 12 months
Retinal fractal dimension
Fractal dimension of the retinal vascular network, calculated using an automated feature extraction applied to Color Fundus Photography images.
Time frame: Baseline to 12 months
Foveal Avascular Zone (FAZ) metrics
Area of the foveal avascular zone measured in square millimeters (mm²) using Optical Coherence Tomography Angiography automated segmentation tools.
Time frame: Baseline to 12 months
Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.
Of 75 non-industry observational studies under Diabetic Retinopathy, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13. This study's planned 12 months is below that.
Counting every sponsor, half of 92 studies reached it within 28 months; a quarter within 12 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Association for Innovation and Biomedical Research on Light and Image